Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases

• US 20090011040A1
• Filed: 05/02/2008
• Published: 01/08/2009
• Est. Priority Date: 05/02/2007
• Status: Abandoned Application

• Current Assignee: Copernicus Therapeutics, Inc., The Board of Regents of the University of Colorado (University of Colorado System)
• Original Assignee: The Board of Regents of the University of Colorado (University of Colorado System)
• Inventors: Naash, Muna I., Cooper, Mark J.
• Application Number:
  US12/150,986
• Publication Number:
  US 20090011040A1
• Time in Patent Office: Days
• US Class Current: 424/501
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/5146 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

The present invention is a method of using compacted nucleic acid (such as DNA) nanoparticles for non-viral gene transfer to various tissues of the human eye or eyes of other mammals. These nanoparticles comprise, in one embodiment, a neutrally-charged complex containing a single molecule of plasmid DNA compacted with polyethylene glycol (PEG)-substituted poly lysine peptides.

Claims

1. A method of treating a subject having an ocular disorder, comprising:

providing a non-viral nanoparticle comprising a compacted nucleic acid molecule linked to a polymer component, wherein the nucleic acid molecule is DNA or RNA and wherein the non-viral nanoparticle has a minor diameter which is less than 25 nm; and

administering the non-viral nanoparticle to an eye of the subject in a manner such that the nucleic acid molecule is transfected within an ocular cell of the eye of the subject and is able to be expressed therein.

2. The method of claim 1 wherein the nucleic acid molecule comprises a gene sequence and a promoter sequence.

3. The method of claim 2 wherein the nucleic acid molecule is constitutively expressed within the ocular cell.

4. The method of claim 1 wherein the non-viral nanoparticle is administered via injection into the subretinal space.

5. The method of claim 1 wherein the non-viral nanoparticle is administered via intravitreal injection.

6. The method of claim 1 wherein the non-viral nanoparticle has an ellipsoidal shape.

7. The method of claim 1 wherein the non-viral nanoparticle has a rod-like shape.

8. The method of claim 1 wherein the ocular disorder to be treated is a disease of the retina or of a portion thereof.

9. The method of claim 8 wherein the ocular disorder is Usher syndrome, Stargardt disease, Bardet-Biedl syndrome, Best disease, choroideremia, gyrate-atrophy, retinitis pigmentosa, macular degeneration, Leber Congenital Amaurosis (Leber'"'"'s Hereditary Optic Neuropathy), Blue-cone monochromacy, retinoschisis, Malattia Leventinese, Oguchi Disease, or Refsum disease.

10. The method of claim 1 wherein the nucleic acid molecule comprises at least one of the genes CA4, CRX, FSCN2, GUCA1B, IMPDH1, NR2E3, NRL, PRPF3, PRPF8, PRPF31, PRPH2, RHO, ROM1, RP1, RP9, SEMA4A, TOPORS, ABCA4, CERKL, CNGA1, CNGB1, CRB1, LRAT, MERTK, NRL, PDE6A, PDE6B, PRCD, PROM1, RGR, RLBP1, RP1, RPE65, SAG, TULP1, USH2A, RP2, and RPGR.

11. The method of claim 1 wherein the nucleic acid molecule comprises at least one of the genes ABCA4, ARMS2, C2, C3, CFB, CFH, ERCC6, FBLN5, HMCN1, HTRA1, RAX2 and TLR4, BEST1, C1QTNF5, EFEMP1, ELOVL4, FSCN2, GUCA1B, PRPH2, TIMP3, and RPGR.

12. The method of claim 1 wherein the ocular cell transfected by the non-viral nanoparticle is a cell of the retina, retinal pigment epithelium, macula, ganglion cell layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, outer segments or inner segments of rods and cones, epithelium of the conjunctiva, iris, ciliary body, cornea, or ocular sebaceous gland epithelia.

13. A compacted nanoparticle, comprising:

a nucleic acid linked to a polymer component, the nucleic acid comprising at least one of CA4, CRX, FSCN2, GUCA1B, IMPDH1, NR2E3, NRL, PRPF3, PRPF8, PRPF31, PRPH2, RHO, ROM1, RP1, RP9, SEMA4A, TOPORS, ABCA4, CERKL, CNGA1, CNGB1, CRB1, LRAT, MERTK, NRL, PDE6A, PDE6B, PRCD, PROM1, RGR, RLBP1, RP1, RPE65, SAG, TULP1, USH2A, RP2, RPGR, ABCA4, ARMS2, C2, C3, CFB, CFH, ERCC6, FBLN5, HMCN1, HTRA1, RAX2, TLR4, BEST1, C1QTNF5, EFEMP1, ELOVL4, FSCN2, GUCA1B, PRPH2, TIMP3, and RPGR; and

a promoter sequence; and

wherein the nanoparticle has a minor diameter of less than 25 nm, and wherein the polymer component comprises a PEG molecule covalently linked to a peptide component comprising a terminal cysteine molecule and multiple repeating lysine or arginine residues.

14. A therapeutic nucleic acid composition comprising the nanoparticle of claim 13 disposed within a pharmaceutically-acceptable carrier or vehicle.